Completed Enrollment

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

Trial Summary

Age Range
≥40 years
Conditions the trial is for
Type 2 Diabetes
What the trial is testing?
Tirzepatide, Dulaglutide
Could I receive a Placebo?
No
Enrollment Goal
13299
Trial Dates
May 29, 2020 - Oct 2024
How long will I be in the trial?
The study will last about 54 months and may include up to 35 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have a diagnosis of type 2 diabetes

  • Participants must have confirmed cardiovascular disease

  • Participants must have HbA1c 7.0% to 10.5%

  • Participants must have a body mass index (BMI) 25 kilograms per meter squared (kg/m²)

Participants Must Not:

  • Participants must not have had a major cardiovascular event within the last 60 days

  • Participants must not have type 1 diabetes mellitus

  • Participants must not have a history of severe hypoglycemia and/or hypoglycemia unawareness within the last 6 months

  • Participants must not have a history of proliferative diabetic retinopathy; or diabetic maculopathy; or non-proliferative diabetic retinopathy that requires acute treatment

  • Participants must not be currently planning a coronary, carotid, or peripheral artery revascularization

  • Participants must not have a history of pancreatitis

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources